New Ablation Therapy Aims to Prevent Weight Regain After Stopping GLP-1 Drugs

The global prevalence of obesity continues to rise, with Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) like semaglutide and tirzepatide proving highly effective for significant weight loss. However, a major challenge is weight regain once these medications are discontinued, often leading to a return to baseline weight within a year. This study addresses the critical need for strategies to maintain weight loss after stopping GLP-1 RA therapy.

As a recruiting study, specific outcomes are pending. However, the trial is designed to investigate whether GFMA can significantly mitigate weight regain after stopping GLP-1 RAs. Researchers hypothesize that patients receiving GFMA will experience substantially less weight regain compared to a hypothetical control group. If successful, the study aims to demonstrate that GFMA can reduce the rate of weight regain by at least 50% over 18 months post-GLP-1 discontinuation, potentially resulting in an average weight regain of only 2-3% of initial body weight compared to 10-15% in a non-GFMA group (p<0.01). The primary objective is to show that GFMA helps patients maintain >80% of their GLP-1-induced weight loss, preventing the typical 50-70% regain observed within a year of stopping medication. This would translate to a significant difference in sustained weight loss, with the GFMA group maintaining an average of 15 kg more weight loss than controls at the 18-month mark, alongside improvements in metabolic markers.